Primary biliary cholangitis

@article{Lleo2020PrimaryBC,
  title={Primary biliary cholangitis},
  author={Ana Lleo and Giu-Qiang Wang and Merrill Eric Gershwin and Gideon M. Hirschfield},
  journal={The Lancet},
  year={2020},
  volume={396},
  pages={1915-1926}
}

Figures and Tables from this paper

Recent advances in clinical practice: epidemiology of autoimmune liver diseases

TLDR
While autoimmune liver diseases are rare, the clinical burden is disproportionately high relative to population incidence and prevalence, and patient morbidity and mortality are reflected by high need for gastroenterology, hepatology and organ transplant services.

Prevalence of Primary Biliary Cholangitis in a Cohort of Primary Sjögren’s Syndrome Patients

TLDR
In this cohort of 115 pSS patients followed up in an outpatient clinic from 1987 to 2020, only one patient showed biochemical and clinical progression of PBC, with increasing alkaline phosphatase and total bilirubin levels, eventually progressing to cirrhosis during follow-up.

Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives

TLDR
Given their low immunogenicity, prominent immunomodulation property, differentiation potential, and tissue maintenance capacity, mesenchymal stem cells (MSCs) are emerging as new options for treating liver diseases, including PBC.

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

TLDR
Ciprofibrate appears to be at least as effective as bezafibrate and should be assessed in large clinical trials as a possibly new, cheaper, and promising option for treatment of UDCA-unresponsive PBC patients.

The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic

TLDR
Together, PBC patients show significant alterations in their salivary microbiota, likely representing one cause and treatment target of oral inflammation and worsening liver functions.

Antimitochondrial Antibodies: from Bench to Bedside

TLDR
Albeit being highly specific for PBC diagnosis, AMA can be detected in less than 1% of healthy subjects, and thus the management subjects with no sign or symptom of liver disease is still a challenge and data concerning clinical risk of developing PBC in this subgroup of patients are controversial.

Molecular Pathogenesis of Intrahepatic Cholestasis of Pregnancy

TLDR
Dysregulation of extracellular matrix and oxygen supply, organelle dysfunction, and epigenetic changes are also found to cause ICP, illuminating more potential drug targets for interfering with.

Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis

TLDR
Despite availability of treatments for PBC, the PBC population had a higher burden of comorbidities than non-cases, with a particularly high prevalence of sleep disorders and depression/anxiety, and a need for treatments specifically indicated for cholestatic pruritus.

References

SHOWING 1-10 OF 355 REFERENCES

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

TLDR
The authors discuss the current understanding of primary biliary cholangitis pathogenesis and highlight implications for new therapies.

Primary biliary cirrhosis

The immunobiology and pathophysiology of primary biliary cirrhosis.

TLDR
A better understanding of the mechanism for selective biliary cell destruction is resulted and genome-wide association studies suggest an important role for the IL-12 pathway in disease susceptibility.

Primary Autoimmune Cholangitis: An Alternative to Antimitochondrial Antibody‐Negative Primary Biliary Cirrhosis

TLDR
Although clinically, biochemically, and histopathologically comparable to primary biliary cirrhosis, autoimmune cholangitis abdicates antimitochondrial antibodies in favor of antinuclear antibodies, for which conventional immunosuppressive therapy does not appear warranted.

Primary biliary cirrhosis

TLDR
The most specific feature differentiating primary biliary cirrhosis from other causes of intrahepatic cholestasis is demonstration of antimitochondrial antibodies and the typical histology.

Animal Models of Primary Biliary Cirrhosis

TLDR
Recent data of selected PBC models, particularly spontaneous models, xenobiotic immunized models, and infection-triggered models are reviewed, clear that a combination of genetic predisposition, environmental factors, and immunological dysfunction contribute to the pathogenesis of PBC.

Genetic association studies and the risk factors for developing the “Immuno‐bile‐logic” disease primary biliary cholangitis

TLDR
Clinician investigators have now assembled genetic risk data for patients whose heritages span Europe, Japan, and Han Chinese, to compare genetic risk by heritage, and further refine which biologic pathways are particularly important for additional targeted investigation in disease-relevant tissues.

Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

TLDR
Fen ofibrate appears to be significantly effective in treating patients with aPBC who respond incompletely to UDCA alone, and combination therapy using fenofibrate and UDCA might be related to the anti-immunological effects, such as the suppression of AMA production as well as its anti-inflammatory effect.

Pediatric-onset primary biliary cirrhosis.

...